Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
Scand J Immunol ; 77(6): 452-9, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23521186

ABSTRACT

The vaccine potential of meningococcal Omp85 was studied by comparing the immune responses of genetically modified deoxycholate-extracted outer membrane vesicles, expressing five-fold higher levels of Omp85, with wild-type vesicles. Groups (n = 6-12) of inbred and outbred mouse strains (Balb/c, C57BL/6, OFI and NMRI) were immunized with the two vaccines, and the induced antibody levels and bactericidal and opsonic activities measured. Except for Balb/c mice, which were low responders, the genetically modified vaccine raised high Omp85 antibody levels in all mouse strains. In comparison, the wild-type vaccine gave lower antibody levels, but NMRI mice responded to this vaccine with the same high levels as the modified vaccine in the other strains. Although the vaccines induced strain-dependent Omp85 antibody responses, the mouse strains showed high and similar serum bactericidal titres. Titres were negligible with heterologous or PorA-negative meningococcal target strains, demonstrating the presence of the dominant bactericidal PorA antibodies. The two vaccines induced the same opsonic titres. Thus, the genetically modified vaccine with high Omp85 antibody levels and the wild-type vaccine induced the same levels of functional activities related to protection against meningococcal disease, suggesting that meningococcal Omp85 is a less attractive vaccine antigen.


Subject(s)
Antibodies, Bacterial/immunology , Bacterial Outer Membrane Proteins/immunology , Meningococcal Vaccines/immunology , Animals , Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Electrophoresis, Polyacrylamide Gel , Female , Immunoblotting , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Recombinant Proteins/immunology
2.
Clin Vaccine Immunol ; 16(4): 528-34, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19225076

ABSTRACT

Following a long-distance outbreak of Legionnaires' disease from an industrial air scrubber in Norway in 2005, a seroepidemiological study measuring levels of immunoglobulin G (IgG) and IgM antibodies to Legionella pneumophila was performed with a polyvalent enzyme-linked immunosorbent assay. One year after the outbreak, IgG levels in employees (n = 213) at the industrial plant harboring the scrubber and in blood donors (n = 398) from the outbreak county were low but significantly higher (P < or = 0.002) than those in blood donors (n = 406) from a nonexposed county. No differences in IgM levels among the three groups were found after adjustment for gender and age. Home addresses of the seroresponders in the exposed county clustered to the city of the outbreak, in contrast to the scattering of addresses of the seroresponding donors in the nonexposed county. Factory employees who operated at an open biological treatment plant had significantly higher IgG and IgM levels (P < or = 0.034) than those working >200 m away. Most of the healthy seroresponders among the factory employees worked near this exposure source. Immunoblotting showed that IgG and IgM antibodies in 82.1% of all seroresponders were directed to the lipopolysaccharide of the L. pneumophila serogroup 1 outbreak strain. In conclusion, 1 year after the long-distance industrial outbreak a small increase in IgG levels of the exposed population was observed. The open biological treatment plant within the industrial premises, however, constituted a short-distance exposure source of L. pneumophila for factory employees working nearby.


Subject(s)
Disease Outbreaks , Legionella pneumophila/immunology , Legionnaires' Disease/epidemiology , Adolescent , Adult , Aged , Antibodies, Bacterial/blood , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Middle Aged , Norway/epidemiology , Occupational Exposure , Seroepidemiologic Studies , Young Adult
3.
Eur J Clin Microbiol Infect Dis ; 27(6): 461-5, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18293018

ABSTRACT

The aim of this study was to measure the seroprevalence to mumps in Norwegian conscripts belonging to the first children vaccination cohorts that had been offered two doses of MMR vaccine. The seroprevalence to mumps was 76% with the Microimmune assay and 85% with the Enzygnost assay. We also compared the performance of the Microimmune assay for detection of mumps- and measles-specific IgG antibodies in 340 paired serum and oral fluid samples from the conscripts and evaluated the effect of revaccination. Mumps-specific IgG antibodies were detected in only 61% of the oral fluids. In contrast, high levels of measles-specific IgG antibodies were detected in both the serum and oral fluid samples. Based on these results, we are only able to recommend the use of oral fluid for surveillance of measles in Norway. Our results may also indicate that the seroprevalence necessary to interrupt transmission of mumps has not been reached in vaccinated young adult Norwegians. Seroconversion was observed in all initially measles seronegative conscripts after revaccination, whereas 23 of 27 initially mumps seronegative conscripts failed to seroconvert.


Subject(s)
Antibodies, Viral/analysis , Immunoglobulin M/analysis , Measles virus/isolation & purification , Measles-Mumps-Rubella Vaccine/administration & dosage , Measles-Mumps-Rubella Vaccine/immunology , Mumps virus/isolation & purification , Saliva/virology , Adolescent , Adult , Antibodies, Viral/blood , Cohort Studies , Humans , Immunization , Measles/prevention & control , Measles virus/immunology , Military Personnel , Mouth , Mumps/diagnosis , Mumps/immunology , Mumps/prevention & control , Mumps virus/immunology , Norway/epidemiology , Saliva/immunology , Seroepidemiologic Studies
4.
Clin Vaccine Immunol ; 14(7): 830-8, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17494638

ABSTRACT

This study presents detailed analyses of total and specific serum antibody levels among 26 and 24 adult volunteers before vaccination and after the third dose of the meningococcal serogroup B outer membrane vesicle (OMV) vaccines MeNZB and MenBvac, respectively, in a clinical trial in New Zealand (V. Thornton, D. Lennon, K. Rasanathan, J. O'Hallahan, P. Oster, J. Stewart, S. Tilman, I. Aaberge, B. Feiring, H. Nokleby, E. Rosenqvist, K. White, S. Reid, K. Mulholland, M. J. Wakefield, and D. Martin, Vaccine 24:1395-1400, 2006). With the homologous vaccine strains as targets, both vaccines induced significant increases in serum bactericidal and opsonophagocytic activities and in the levels of immunoglobulin G (IgG) to OMV antigens in an enzyme-linked immunosorbent assay (ELISA) and to live meningococci by flow cytometry. They also induced high levels of activity against the heterologous strains, particularly in terms of opsonophagocytic activity and IgG binding to live bacteria. The antibody levels with the homologous and heterologous strains in the four assays showed high and significant positive correlations. Specific IgG binding to 10 major OMV antigens in each vaccine was measured by scanning of immunoblots; ELISAs for two antigens, lipopolysaccharide and Neisseria surface protein A (NspA), were also performed. Both vaccines elicited significant increases in IgG binding to all homologous and heterologous OMV antigens except NspA. The total IgG band intensity on the blots correlated significantly with the IgG levels determined by the OMV ELISA and flow cytometry. In conclusion, the results of the various immunological assays showed that both OMV vaccines gave rise to high levels of specific and cross-reacting antibodies.


Subject(s)
Meningococcal Infections/immunology , Meningococcal Infections/prevention & control , Meningococcal Vaccines/administration & dosage , Neisseria meningitidis, Serogroup B/immunology , Polysaccharides, Bacterial/administration & dosage , Polysaccharides, Bacterial/immunology , Adolescent , Adult , Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Bacterial Capsules , Bacterial Outer Membrane Proteins/administration & dosage , Bacterial Outer Membrane Proteins/immunology , Enzyme-Linked Immunosorbent Assay , Humans , Immunoblotting , Immunoglobulin G/blood , Lipopolysaccharides/administration & dosage , Lipopolysaccharides/immunology , Meningococcal Vaccines/immunology , Middle Aged , New Zealand , Phagocytosis/immunology
5.
Methods Mol Med ; 66: 275-88, 2001.
Article in English | MEDLINE | ID: mdl-21336761

ABSTRACT

This chapter will describe the use of the immunoblotting method for analysing antibody specificities towards meningococcal antigens in sera from vaccinees, receiving group B meningococcal outer-membrane vesicle (OMV) vaccines, or from patients, falling ill with meningococcal disease. The power of the blotting technique lies in the simultaneous identification of many immunogenic components in a sample. Within the meningococcal field, this method has been employed in analyzes of antibody specificities of sera from vaccinees (1-6), patients (7-10), and carriers (11,12) as well as for characterization of OMV vaccines (13,14). Some of these studies present various ways of quantifying the blotting results (5,7,9,11).

6.
Methods Mol Med ; 67: 131-45, 2001.
Article in English | MEDLINE | ID: mdl-21337142

ABSTRACT

Immunoassays employ a range of methods to detect and quantify antigens or antibodies and to study the composition of antigens. This chapter describes four useful immunoassays for serological characterization of antigens of Neisseria meningitidis: whole-cell enzyme-linked immunosorbent assay (ELISA); dot blot, colony blot, and immunoblot. Serological characterization of N. meningitidis antigens is valuable for epidemiological studies as well as for identifying immunologically important antigens in vaccine development (1,2). Typing of N. meningitidis is based on the immunological detection of specific epitopes on the outer-membrane proteins (OMP) and lipopolysaccharides (LPS) (3), and panels of monoclonal antibodies (MAbs) have been developed by several laboratories to refine the serological classification system (4-8). Differences in capsular polysaccharides determine the meningococcal serogroup, whereas the serotypes and serosubtypes are based on antigenic differences of the PorB OMP and PorA OMP, respectively (3). The PorA protein contains two variable loops (VR1 and VR2), each of which determine a dis- tinct set of serosubtypes. Thus the serosubtypes of an isolate can include two independent designations (9-11). Variation in the oligosaccharide moiety of the LPS determines the immunotype, and more than one epitope can be present in the same population of a single isolate (6,12). In the current typing scheme the classification is given as [serogroup]: [serotype]: [serosubtype]: [immunotype], e.g., B: 15:P1.7,16:L3,7,9.

7.
J Immunol Methods ; 244(1-2): 9-15, 2000 Oct 20.
Article in English | MEDLINE | ID: mdl-11033014

ABSTRACT

IgG antibody levels to the meningococcal PorA and PorB proteins in 56 acute and convalescent phase sera from 25 patients with meningococcal disease were compared by immunoblotting and ELISA. Heat-treated outer membrane vesicles from strain 44/76 (B:15:P1.7, 16) served as antigens for immunoblotting, whereas purified P1.7,16 PorA and P15 PorB from the same strain were used as antigens in the ELISA. In the blotting method, IgG binding to the porins was determined by digital scanning of the immunoreactive bands and calculated relative to the PorA binding of a reference serum on each blot. The coefficient of variation for the reference serum was 21.6% (a total of 144 strips) with smaller variations for each day's experiments. Blotting of all 56 sera at the standard 1/200 dilution measured anti-PorA and anti-PorB levels that correlated with those obtained by ELISA (Spearman rank-order correlation coefficient r(s)=0.48; P<0.001). At this dilution, the anti-PorA (r(s)=0.52; P<0. 004) and anti-PorB (r(s)=0.60; P<0.001) levels of the convalescent phase sera (n=29) corresponded with the ELISA measurements, whereas no correlation was found with the results for the acute phase sera, which mostly had low ELISA antibody levels (<2 microg/ml IgG). A corresponding blot analysis of convalescent sera from the seven patients, who had received the 44/76 outer membrane vesicle vaccine, demonstrated a high correlation coefficient for the anti-PorA levels (r(s)=0.95; P<0.001) vs. the ELISA results. No such correlation was observed for the PorB response in these sera, being nine-fold higher than the PorA response, because of a prozone effect on the blots at the standard dilution. However, blotting at a higher serum dilution (1/2000) resulted in anti-PorB levels that also correlated strongly (r(s)=0.93 P<0.001) with the ELISA measurements.


Subject(s)
Bacterial Outer Membrane Proteins/immunology , Immunoglobulin G/blood , Meningococcal Infections/immunology , Neisseria meningitidis/immunology , Porins/immunology , Antigens, Bacterial/blood , Antigens, Bacterial/immunology , Antigens, Bacterial/metabolism , Bacterial Outer Membrane Proteins/metabolism , Bacterial Vaccines/immunology , Bacterial Vaccines/therapeutic use , Enzyme-Linked Immunosorbent Assay , Humans , Immunoblotting , Immunoglobulin G/metabolism , Meningococcal Infections/prevention & control , Porins/metabolism
8.
Clin Diagn Lab Immunol ; 7(3): 390-5, 2000 May.
Article in English | MEDLINE | ID: mdl-10799451

ABSTRACT

The ET-15 clone within the electrophoretic type (ET)-37 complex of Neisseria meningitidis was first detected in Canada in 1986 and has since been associated with outbreaks of meningococcal disease in many parts of the world. While the majority of the strains of the ET-37 complex are serosubtype P1.5,2, serosubtype determination of ET-15 strains may often be incomplete, with either only one or none of the two variable regions (VRs) of the serosubtype PorA outer membrane protein reacting with monoclonal antibodies. DNA sequence analysis of the porA gene from ET-15 strains with one or both unidentified serosubtype determinants was undertaken to identify the genetic basis of the lack of reaction with the monoclonal antibodies. Fourteen different porA alleles were identified among 38 ET-15 strains from various geographic origins. The sequences corresponding to subtypes P1.5a,10d, P1.5,2, P1.5,10d, P1.5a,10k, and P1.5a,10a were identified in 18, 11, 2, 2, and 1 isolate, respectively. Of the remaining four strains, which all were nonserosubtypeable, two had a stop codon within the VR1 and the VR2, respectively, while in the other two the porA gene was interrupted by the insertion element, IS1301. Of the strains with P1.5,2 sequence, one had a stop codon between the VR1 and VR2, one had a four-amino-acid deletion outside the VR2, and another showed no expression of PorA on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Our results reveal that numerous genetic events have occurred in the porA gene of the ET-15 clone in the short time of its epidemic spread. The magnitude of microevolutionary mechanisms available in meningococci and the remarkable genetic flexibility of these bacteria need to be considered in relation to PorA vaccine development.


Subject(s)
Disease Outbreaks , Genetic Variation , Meningitis, Meningococcal/epidemiology , Meningitis, Meningococcal/genetics , Neisseria meningitidis/genetics , Porins/genetics , Amino Acid Sequence , Base Sequence , Cloning, Molecular , DNA Mutational Analysis , Electrophoresis, Polyacrylamide Gel , Evolution, Molecular , Humans , Immunoblotting , Meningitis, Meningococcal/immunology , Molecular Sequence Data , Neisseria meningitidis/immunology , Polymerase Chain Reaction , Porins/analysis , Porins/immunology
9.
J Clin Immunol ; 20(2): 138-49, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10821465

ABSTRACT

Meningitis caused by Neisseria meningitidis serogroup W-135 was diagnosed in a 14-year-old girl with a history of neonatal septicemia and meningitis caused by group B streptococci type III. C2 deficiency type I was found in the patient and her healthy sister. Both sisters were vaccinated with tetravalent meningococcal vaccine and a conjugate Haemophilus influenzae type b vaccine. Three main points emerged from the analysis. First, vaccination resulted in serum bactericidal responses demonstrating anticapsular antibody-mediated recruitment of the alternative pathway. Second, addition of C2 to prevaccination sera produced bactericidal activity in the absence of anticapsular antibodies, which suggested that the bactericidal action of antibodies to subcapsular antigens detected in the sera might strictly depend on the classical pathway. A third point concerned a previously unrecognized type of blocking activity. Thus, postvaccination sera of the healthy sister contained IgG that inhibited killing of serogroup W-135 in C2-deficient serum, and the deposition of C3 on enzyme-linked immunosorbent assay plates coated with purified W-135 polysaccharide. Our findings suggested blocking to be serogroup-specific and dependent on early classical pathway components. Retained opsonic activity probably supported post-vaccination immunity despite blocking of the bactericidal activity. The demonstration of functional vaccination responses with recruitment of alternative pathway-mediated defense should encourage further trial of capsular vaccines in classical pathway deficiency states.


Subject(s)
Bacterial Outer Membrane Proteins/immunology , Complement C2/deficiency , Complement Pathway, Alternative/immunology , Haemophilus Vaccines/immunology , Haemophilus influenzae type b/immunology , Hyaluronan Receptors , Immunoglobulin G/biosynthesis , Membrane Glycoproteins , Meningitis, Haemophilus/immunology , Meningitis, Meningococcal/immunology , Neisseria meningitidis/immunology , Polysaccharides, Bacterial/immunology , Adolescent , Antibodies, Blocking/biosynthesis , Carrier Proteins , Child, Preschool , Complement C2/immunology , Female , Genetic Markers/immunology , Humans , Mitochondrial Proteins , Opsonin Proteins/metabolism , Phagocytosis/immunology , Receptors, Complement/metabolism , Serotyping , Vaccines, Inactivated/immunology
10.
Vaccine ; 18(18): 1910-9, 2000 Mar 17.
Article in English | MEDLINE | ID: mdl-10699340

ABSTRACT

Whole killed meningococci (Nm) and pertussis bacteria (Bp) were tested for mucosal immunogenicity and as mucosal adjuvants for an inactivated influenza virus vaccine given intranasally to unanaesthetized mice. Virus was given alone, or simply mixed with one of the bacterial preparations, in four doses at weekly intervals. The virus alone induced low but significant increases of influenza-specific IgG antibodies in serum measured by ELISA, whereas IgA responses in serum and saliva were insignificant compared to non-immunized controls. With Bp or Nm admixed, serum IgG and IgA and salivary IgA responses to the influenza virus were substantially augmented (P<0.005). However, this adjuvant effect of the bacterial preparations was not significant for responses in the intestine as measured by antibodies in faeces. Antibody responses to Bp itself, but not to Nm, were inhibited by the admixture of the virus vaccine. Moreover, the pertussis preparation induced salivary antibodies which cross-reacted with Nm. Whole-cell bacteria with inherent strong mucosal immunogenicity may also possess mucosal adjuvanticity for admixed particulate antigens which are weakly immunogenic by the nasal route.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Bordetella pertussis/immunology , Influenza Vaccines/immunology , Nasal Mucosa/immunology , Neisseria meningitidis/immunology , Orthomyxoviridae Infections/immunology , Administration, Intranasal , Animals , Antibodies, Bacterial/biosynthesis , Antibodies, Viral/biosynthesis , Feces/microbiology , Feces/virology , Female , Immunoglobulin A/biosynthesis , Mice , Mice, Inbred BALB C , Orthomyxoviridae/immunology , Vaccines, Inactivated/immunology
11.
J Med Microbiol ; 49(2): 157-163, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10670566

ABSTRACT

A whole-cell pertussis vaccine, each dose consisting of 250 microg of protein, was given intranasally four times at weekly intervals to six adult volunteers. All vaccinees responded with increases in nasal fluid IgA antibodies to Bordetella pertussis whole-cell antigen. Three vaccinees with high nasal antibody responses also developed increased serum IgA and IgG antibodies to this antigen. Salivary antibody responses to the whole-cell antigen, as well as antibodies in serum and secretions to pertussis toxin (PT) and filamentous haemagglutinin (FHA) were negligible, except for a moderate increase in nasal fluid antibodies to FHA. Unexpectedly, the same vaccinees developed significant rises in nasal and salivary IgA antibodies to meningococcal outer-membrane antigens, whereas corresponding serum IgA and IgG antibodies were unchanged. Thus it appears that mucosal immunisation may induce secretory antibodies with broader specificities than can be found in serum.


Subject(s)
Antibodies, Bacterial/biosynthesis , Bordetella pertussis/immunology , Immunity, Mucosal , Pertussis Vaccine/administration & dosage , Pertussis Vaccine/immunology , Adhesins, Bacterial/immunology , Administration, Intranasal , Adult , Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Bacterial Vaccines/immunology , Cross Reactions , Female , Hemagglutinins/immunology , Humans , Immunization Schedule , Immunoglobulin A/biosynthesis , Immunoglobulin A/blood , Immunoglobulin A, Secretory/biosynthesis , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Male , Middle Aged , Nasal Mucosa/immunology , Neisseria meningitidis/immunology , Pertussis Toxin , Pertussis Vaccine/adverse effects , Porins/immunology , Saliva/immunology , Virulence Factors, Bordetella/immunology
12.
Vaccine ; 17(20-21): 2677-89, 1999 Jun 04.
Article in English | MEDLINE | ID: mdl-10418919

ABSTRACT

The infant rat infection model previously developed to evaluate protective ability of passively administered murine antibodies to group B meningococcal (MenB) surface antigens was adapted for human sera. Several challenge doses were tested, aiming at sensitive detection of protection with little interassay variability. Doses of 10(5) and 10(6) colony forming units of strain IH5341 (MenB:15:P1.7,16) injected intraperitoneally gave consistently high levels of bacteremia and meningitis developed in 6 h in 50-100% of the pups. A monoclonal antibody mAb735 to the MenB capsule, injected 1-2 h before bacterial challenge, gave full protection at a dose of 2 microg/pup. Sera from adult volunteers immunized with a MenB outer membrane vesicle vaccine reproducibly reduced bacterial counts in the blood and cerebrospinal fluid, whereas a normal human serum, lacking bactericidal and opsonophagocidal activity, was unprotective.


Subject(s)
Antibodies, Bacterial/immunology , Bacterial Outer Membrane Proteins/immunology , Bacterial Vaccines/immunology , Neisseria meningitidis/immunology , Adult , Animals , Antibodies, Monoclonal/immunology , Bacteremia/prevention & control , Disease Models, Animal , Female , Humans , Meningococcal Infections/prevention & control , Phagocytosis , Rats , Rats, Wistar
13.
Vaccine ; 17(19): 2336-45, 1999 May 14.
Article in English | MEDLINE | ID: mdl-10392615

ABSTRACT

Outer membrane vesicles (OMVs) from group B meningococci induced both serum and mucosal antibodies when given as a nasal and rectal vaccine to mice. Cholera toxin (CT) enhanced the antibody responses in serum both after nasal and rectal immunizations, and the mucosal responses after rectal immunizations only. Nasal immunizations, however, were most effective, with mucosal responses which were not dependent on the use of CT. The serum bactericidal activity was similarly not enhanced by CT, indicating that the positive effect of CT on the serum IgG level was not including bactericidal activity. A small nasal booster dose induced antibody responses in serum as far as eight months after intranasal and subcutaneous immunizations, and in saliva after intranasal immunizations. Nasal vaccines may thus be favorably combined with parenteral vaccines.


Subject(s)
Neisseria meningitidis/immunology , Polysaccharides, Bacterial/immunology , Administration, Intranasal , Animals , Antibodies, Bacterial/analysis , Bacterial Capsules , Blood Bactericidal Activity , Cholera Toxin/pharmacology , Dose-Response Relationship, Immunologic , Female , Immunity, Mucosal , Immunologic Memory , Mice , Mice, Inbred BALB C , Neisseria meningitidis/chemistry , Polysaccharides, Bacterial/administration & dosage
14.
Clin Diagn Lab Immunol ; 6(4): 639-42, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10391880

ABSTRACT

Two reference monoclonal antibodies against the meningococcal P1.15 subtype PorA, MN3C5C and 2-1-P1.15, showed only partial concordant recognition of meningococcal isolates. Cyanogen bromide cleavage of P1.19,15 PorA, peptide mapping, and sequencing of porA regions demonstrated that 2-1-P1.15 was specific for subtype P1.19, and henceforth it is to be redesignated as 2-1-P1.19.


Subject(s)
Neisseria meningitidis/immunology , Porins/chemistry , Antibodies, Bacterial/immunology , Antibodies, Monoclonal/immunology , Antibody Specificity , Base Sequence , Enzyme-Linked Immunosorbent Assay , Epitopes/analysis , Immunoblotting , Molecular Sequence Data , Porins/genetics
16.
Infect Immun ; 67(3): 1267-76, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10024570

ABSTRACT

Antibodies against the class 4 outer membrane protein (OMP) from Neisseria meningitidis have been purified from sera from vaccinees immunized with the Norwegian meningococcal group B outer membrane vesicle vaccine. The human sera and purified antibodies reacted strongly with the class 4 OMP in immunoblots, whereas experiments with whole bacteria showed only weak reactions, indicating that the antibodies mainly reacted with parts of the class 4 molecule that were not exposed. The purified human anti-class 4 OMP antibodies and the monoclonal antibodies (MAbs) were neither bactericidal nor opsonic against live meningococci. Three new MAbs against the class 4 OMP were generated and compared with other, previously described MAbs. Three linear epitopes in different regions of the class 4 OMP were identified by the reaction of MAbs with synthetic peptides. The MAbs showed no blocking effect on bactericidal activity of MAbs against other OMPs. However, one of the eight purified human anti-class 4 OMP antibody preparations, selected from immunoblot reactions among sera from 27 vaccinees, inhibited at high concentrations the bactericidal effect of a MAb against the class 1 OMP. However, these antibodies were not vaccine induced, as they were present also before vaccination. Therefore, this study gave no evidence that vaccination with a meningococcal outer membrane vesicle vaccine containing the class 4 OMP induces blocking antibodies. Our data indicated that the structure of class 4 OMP does not correspond to standard beta-barrel structures of integral OMPs and that no substantial portion of the OmpA-like C-terminal region of this protein is located at the surface of the outer membrane.


Subject(s)
Antibodies, Bacterial/immunology , Bacterial Outer Membrane Proteins/immunology , Epitopes , Neisseria meningitidis/immunology , Adult , Animals , Antibodies, Monoclonal/immunology , Bacterial Vaccines/immunology , Blood Bactericidal Activity , Enzyme-Linked Immunosorbent Assay , Humans , Immunoblotting , Mice , Mice, Inbred BALB C , Microscopy, Immunoelectron
17.
Infect Immun ; 66(7): 3223-31, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9632589

ABSTRACT

Sera from vaccinees and controls who contracted serogroup B meningococcal disease during the blinded and open parts of a two-dose protection trial in Norway were compared for antigen-specific and bactericidal antibodies against vaccine strain 44/76 (B:15:P1.7,16). From 16 of 20 (80%) vaccinees and 26 of 35 (74%) controls, one or more serum samples (n = 104) were collected during the acute phase (1 to 4 days), early convalescent phase (5 to 79 days), and late convalescent phase (8 to 31 months) after onset of disease. Binding of immunoglobulin G (IgG) to the major outer membrane antigens (80- and 70-kDa proteins, class 1, 3, and 5 proteins, and lipopolysaccharide [LPS]) on immunoblots was measured by digital image analysis. Specific IgG levels in vaccinees increased from acute to early convalescent phases, followed by a decline, while controls showed a small increase over time. Vaccinees had significantly higher levels than controls against class 1 and 3 porins and LPS in acute sera, against all antigens during early convalescence, and against class 1 and 3 porins in the later sera. Vaccinees who were infected with strains expressing subtype P1.7,16 proteins demonstrated a level of IgG binding to protein P1.7,16 with early-convalescent-phase sera that was fourfold higher than that of those infected with other strains. Bactericidal titers in serum against the vaccine strain were 192-fold higher for vaccinees than those for controls during early convalescence, but similarly low levels were found during late convalescence. A vaccine-induced anamnestic response of specific and functional antibody activities was thus shown, but the decrease in protection over time after vaccination indicated that two vaccine doses did not induce sufficient levels of long-term protective antibodies.


Subject(s)
Bacterial Outer Membrane Proteins/immunology , Bacterial Vaccines/immunology , Meningococcal Infections/prevention & control , Neisseria meningitidis/immunology , Antibodies, Bacterial/blood , Blood Bactericidal Activity , Enzyme-Linked Immunosorbent Assay , Humans , Immunoglobulin G/blood , Meningococcal Infections/immunology , Molecular Weight , Vaccination
18.
Dev Biol Stand ; 92: 127-33, 1998.
Article in English | MEDLINE | ID: mdl-9554266

ABSTRACT

A Norwegian outer membrane vesicle (OMV) vaccine against group B meningococcal disease proved to be strongly immunogenic when administered intranasally in mice. The OMV preparation, made from Neisseria meningitidis and intended for parenteral use, was therefore given without adjuvant to human volunteers (n = 12) in the form of nose drops or nasal spray. Such immunizations, which were carried out at weekly intervals during a three-week period, were able to induce systemic antibodies with bactericidal activity in more than half of the individuals. In addition, all vaccinees developed marked increases in OMV-specific IgA antibodies in nasal secretions. The potential of the OMV particles as carriers for other less immunogenic antigens were elucidated in mice with use of whole inactivated influenza virus. Even though influenza virus alone did induce some systemic and salivary antibody responses after being administered intranasally, these responses were greatly augmented when the virus was presented together with OMVs. Thus, it is possible that a nasal OMV vaccine may induce protection against invasive meningococcal disease, and also that it might be used as a vehicle for nasal vaccines against other diseases.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Bacterial Vaccines/therapeutic use , Meningococcal Infections/prevention & control , Neisseria meningitidis/immunology , Administration, Intranasal , Adult , Animals , Antibodies, Bacterial/biosynthesis , Blood Bactericidal Activity , Humans , Immunoglobulin A/biosynthesis , Immunoglobulin G/biosynthesis , Influenza A virus/immunology , Influenza Vaccines/administration & dosage , Influenza Vaccines/therapeutic use , Influenza, Human/prevention & control , Meningococcal Infections/immunology , Meningococcal Vaccines , Mice
19.
Infect Immun ; 66(4): 1334-41, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9529050

ABSTRACT

A nasal vaccine, consisting of outer membrane vesicles (OMVs) from group B Neisseria meningitidis, was given to 12 volunteers in the form of nose drops or nasal spray four times at weekly intervals, with a fifth dose 5 months later. Each nasal dose consisted of 250 microg of protein, equivalent to 10 times the intramuscular dose that was administered twice with a 6-week interval to 11 other volunteers. All individuals given the nasal vaccine developed immunoglobulin A (IgA) antibody responses to OMVs in nasal secretions, and eight developed salivary IgA antibodies which persisted for at least 5 months. Intramuscular immunizations did not lead to antibody responses in the secretions. Modest increases in serum IgG antibodies were obtained in 5 volunteers who had been immunized intranasally, while 10 individuals responded strongly to the intramuscular vaccine. Both the serum and secretory antibody responses reached a maximum after two to three doses of the nasal vaccine, with no significant booster effect of the fifth dose. The pattern of serum antibody specificities against the different OMV components after intranasal immunizations was largely similar to that obtained with the intramuscular vaccine. Five and eight vaccinees in the nasal group developed persistent increases in serum bactericidal titers to the homologous meningococcal vaccine strain expressing low and high levels, respectively, of the outer membrane protein Opc. Our results indicate that meningococcal OMVs possess the structures necessary to initiate systemic as well as local mucosal immune responses when presented as a nasal vaccine. Although the serum antibody levels were less conspicuous than those after intramuscular vaccinations, the demonstration of substantial bactericidal activity indicates that a nonproliferating nasal vaccine might induce antibodies of high functional quality.


Subject(s)
Antibodies, Bacterial/biosynthesis , Bacterial Vaccines/immunology , Neisseria meningitidis/immunology , Administration, Intranasal , Adult , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Bacterial Vaccines/administration & dosage , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunity, Mucosal , Male , Middle Aged
20.
Microbiology (Reading) ; 142 ( Pt 9): 2491-8, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8828216

ABSTRACT

Neisserial porins, the major protein constituents of the outer membrane capable of inducing antibody responses in humans, are considered to be meningococcal vaccine candidates, so it is important to map the relevant B-cell epitopes. For B-cell epitope analyses of the serotype 15 PorB protein in Neisseria meningitidis, paired sera from selected patients with systemic meningococcal disease (SMD) were screened with synthetic 12mer peptides spanning the PorB protein sequence, and/or its variable region 1 (VR1). A 'SMD-related' linear B-cell epitope was found within the VR1 region consisting of 14 residues (17svFHQNGQVTEvtt30). A 23mer soluble peptide (D63b2) that covered the VR1 region, including the complete 17svFHQNGQVTEvtt30 sequence, was recognized, whereas no detectable binding was observed to a 16mer peptide (D63a1) containing most of the essential sequence (19FHQNGQVTEvtt30). A low frequency of IgG responses specific for the PorB linear epitopes was found in convalescent-phase sera from 132 SMD patients studied, as judged from both immunoblotting studies (24/132; 18.2%) and reactivity with peptide D63b2 (18/132; 13.6%). Peptide D63b2 significantly inhibited IgG binding to the denatured PorB protein on immunoblots, suggesting that this B-cell epitope was one of the main linear epitopes on the PorB protein recognized by sera from some SMD patients.


Subject(s)
B-Lymphocytes/immunology , Bacterial Outer Membrane Proteins/immunology , Meningococcal Infections/immunology , Neisseria meningitidis/immunology , Porins , Adolescent , Adult , Antigenic Variation , Bacterial Proteins/immunology , Child , Child, Preschool , Epitope Mapping , Female , Humans , Immunoblotting , Immunoglobulin G/immunology , Male , Middle Aged , Peptides/chemical synthesis , Peptides/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...